| Name | Title | Contact Details |
|---|---|---|
Wendy Vargas |
VP Global CO Project Leader Head, Rare Disease, Rare Blood Disorders, Oncology | Profile |
Sophie Forge |
VP - Global Head of Digital R&D Pipeline and Project analytics | Profile |
Andrey Malyy |
Global Head of Information Technology Solutions, Innovation, CX and Mobile | Profile |
Arnaud Robert |
Executive Vice President and Chief Digital Officer | Profile |
Michael Shanno |
Head of Digital and Information Technology | Profile |
Vapotherm Inc., is a publicly held corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.
Morris and Dickson Co. is a Shreveport, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VIATRIS™ is a new kind of global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of approximately ~45,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for US, European and other world markets.
Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.